Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR mutations (EGFR-M+). Patients and methods: We conducted a literature-based meta-analysis to quantify the magnitude of b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A., Scagliotti, G. V., Cognetti, F., Giannarelli, D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2011
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3202146/
https://ncbi.nlm.nih.gov/pubmed/21325444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdq742
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados